Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the ...

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

Moderna’s new combination vaccine for seasonal influenza and COVID-19 has outperformed current standard vaccines in a large phase 3 clinical trial, showing stronger immune responses to both viruses in ...

A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the ... the immunotherapy in a vaccine, called nivolumab ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

against several different viruses beyond covid, and Moderna has several such programs in clinical development. Among Moderna's infectious-disease vaccine programs, endemic respiratory viruses are ...

Last week, Moderna pushed its target date for the vaccine’s approval to 2026 after the Food and Drug Administration requested a more direct measure: how much the shot lowered the risk of disease.

especially when compared to traditional vaccine-makers. Moderna has more than 40 mRNA-based investigational candidates in different stages of clinical studies, targeting various indications ...

The Trump administration stopped the study. Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against ...